Welcome to our dedicated page for Amedisys SEC filings (Ticker: AMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amedisys, Inc. (AMED) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, along with AI-powered summaries to help interpret complex disclosures. As a former Nasdaq-listed healthcare at home company, Amedisys filed a range of reports that describe its home health, hospice and high acuity care businesses, financial performance, risk factors and corporate transactions.
Investors reviewing Amedisys filings will find annual reports on Form 10-K and quarterly reports on Form 10-Q that detail net service revenue, operating expenses, net income, cash flows, balance sheet data and non-GAAP measures such as adjusted EBITDA and adjusted net income. These filings also include discussions of reimbursement, regulatory risk, competition in the healthcare industry, and operational considerations such as staffing and referral relationships. Stock Titan’s AI tools can highlight key sections, summarize segment performance and explain the implications of accounting and non-GAAP adjustments.
Current Reports on Form 8-K are particularly important for understanding major events affecting Amedisys. For example, an August 14, 2025 Form 8-K describes the completion of the merger between Amedisys and a wholly owned subsidiary of UnitedHealth Group, under which Amedisys became a wholly owned subsidiary of UnitedHealth Group and Amedisys common stock was converted into the right to receive cash consideration. Related 8-K items discuss the termination of senior credit facilities, changes in control, board resignations and amendments to corporate governance documents.
The filings set also includes Form 25 notifications filed in August 2025 regarding the removal of Amedisys common stock from listing on the Nasdaq Stock Market and deregistration under Section 12(b) of the Exchange Act, as well as a Form 15 filed on August 25, 2025 to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d). These documents mark Amedisys’ transition from a public company to a wholly owned subsidiary of UnitedHealth Group. On Stock Titan, users can use AI-generated overviews to quickly understand these changes, while still having access to the full text of each SEC filing for detailed review.
Allyson Guidroz, the Chief Accounting Officer of Amedisys Inc. (AMED), was awarded 2,015 time-based restricted stock units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of the issuer's common stock and will vest 50% on August 6, 2026 and 50% on August 6, 2027, provided the reporting person remains continuously employed on those dates. The award is recorded at a $0 price in this filing.
Following the reported transaction the filing shows the reporting person beneficially owns 9,472 shares. The report references a plan statement dated June 30, 2025 and was signed on behalf of the reporting person by Jennifer Guckert Griffin on 08/08/2025.
On 7 Aug 2025 the U.S. Department of Justice and the Attorneys General of MD, IL, NJ and NY filed a Proposed Final Judgment with the U.S. District Court for Maryland. The order—agreed to by Amedisys (AMED) and UnitedHealth Group—would settle the government’s antitrust lawsuit against their June 26 2023 merger agreement (waiver dated 26 Dec 2024). If approved, the companies must divest specified assets within 75 days of an Asset Preservation/Hold-Separate order, or within 60 days after all Indiana and West Virginia clearances, whichever is later.
The judgment requires court approval under the Antitrust Procedures and Penalties Act and the merger still depends on the remaining closing conditions in the Merger Agreement. No financial results, consideration changes or new guidance were provided.
- Filing: Form 8-K, Item 8.01 – Other Events
- Ticker: AMED; Exchange: NASDAQ Global Select
- Key risks noted: potential deal termination, regulatory delays, litigation, integration distraction and inability to complete divestitures.
Implication: The settlement framework reduces regulatory uncertainty but completion risk persists until the court rules and divestiture terms are executed.
Q2 2025 snapshot: Net service revenue rose 5.2% to $621.9 m, but operating income slid 12.7% to $45.6 m as merger-related expenses jumped to $26.3 m. Net income attributable to Amedisys fell 13% to $28.1 m, driving diluted EPS down to $0.84 from $0.98 a year ago.
Year-to-date: First-half revenue climbed 4.7% to $1.22 bn. A $48.1 m gain from the Medalogix equity rollover propelled net income 92% higher to $89.1 m (EPS $2.68). Operating cash flow improved to $63.5 m, lifting cash to $337.3 m. Debt consists mainly of a $338.1 m term loan at 5.9%; the $550 m revolver remains undrawn, and total equity increased to $1.27 bn.
Balance-sheet & liquidity: Current ratio strengthened (assets $662 m vs liabilities $488 m). No covenant breaches reported after extending the credit facility maturity to 30 Jul 2027.
Strategic & regulatory: The $101-per-share merger with UnitedHealth is contested by the DOJ; trial is pencilled in for 27 Oct 2025 and the outside date extended to 31 Dec 2025. Planned divestitures to BrightSpring and Pennant depend on DOJ approval. Management highlights 68% Medicare concentration, ongoing labor tightness and audit exposure as key risks.
Amedisys Inc. (AMED) – Form 4 filing overview
Director Bruce D. Perkins reported one transaction dated 07/01/2025. Using transaction code “G” (gift), Perkins transferred 105 shares of Amedisys common stock at a stated price of $0. Following the gift, the director’s direct beneficial ownership stands at 23,992 shares.
The filing does not disclose any derivative security activity and contains no additional explanatory remarks beyond the standard signature block.
- Size of transaction: ~0.4 % of the director’s post-transaction holdings
- Insider relationship: Director (non-executive)
- Ownership form: Direct
No other material financial data, earnings information, or strategic commentary is included in this short Form 4.